Analyst Ratings for SpringWorks Therapeutics
Portfolio Pulse from Benzinga Insights
SpringWorks Therapeutics (NASDAQ:SWTX) has received 4 bullish analyst ratings in the last quarter, with no neutral or bearish ratings. The average 12-month price target for SWTX is $61.75, with a high of $73.00 and a low of $52.00. This target has increased by 2.92% from the previous target of $60.00. Analyst ratings are opinions on stock performance based on research and are updated quarterly.
November 29, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SpringWorks Therapeutics has received a unanimous bullish outlook from analysts, with an increased average price target of $61.75, suggesting a positive sentiment towards the stock.
The unanimous bullish ratings from analysts and the increase in the average price target indicate a strong positive sentiment, which is likely to influence investor perception and could lead to a short-term increase in the stock price of SWTX.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100